Treatment of clozapine‐associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial ( CODEX )
Abstract
Clozapine causes obesity and type 2 diabetes (T2DM). Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (e.g. exenatide) can counter clozapine‐associated GLP‐1 dysregulation in animals, and may be beneficial in people on clozapine. This randomized, controlled, open‐label, pilot trial evaluated weekly exenatide for weight loss among clozapine‐treated obese adults with schizophrenia, with or without T2DM. A total of 28 outpatients were randomized to once‐weekly extended‐release subcutaneous exenatide or usual care for 24 weeks. The primary outcome was proportion of participants with >5% weight loss. All 28 participants completed the study; 3/14 in the exenatide group and 2/14 in the usual care group had T2DM. Six people on exenatide achieved >5% weight loss vs one receiving usual care ( P = .029). Compared with usual care, participants on exenatide had greater mean weight loss (−5.29 vs −1.12 kg; P = .015) and body mass index reduction (−1.78 vs −0.39 kg/m 2 ; P = .019), and reduced fasting glucose (−0.34 vs 0.39 mmol/L; P = .036) and glycated haemoglobin levels (−0.21% vs 0.03%; P = .004). There were no significant differences in other metabolic syndrome components. Exenatide may be a promising therapeutic agent for glycaemic control and weight loss in clozapine‐treated people with obesity, and could assist in reducing clozapine‐associated cardio‐metabolic morbidity and mortality.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Preliminary evidence supports the efficacy of GLP-1 receptor agonists in antipsychotic-associated weight gain.
“with preliminary evidence supporting efficacy in AAWG.”
From Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series (2023) · cites this paper as [53]
Even modest improvements in fitness are associated with a 15% decrease in mortality in the general population.
“This can also produce important health benefits, as even modest improvements in fitness are associated with a 15% decrease in mortality in the general population.281”
From The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness (2019) · cites this paper as [281]
Cites
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · see citing works
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914 · see citing works
Siskind, D. J., McCartney, L., Goldschlager, R., & Kisely, S. R. (2016) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.115.177261 · Cited by 605 · see citing works
Self-citationLarsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1220 · Cited by 250 · see citing works
Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and Mortality
Henderson, D. C., Nguyen, D. D., Copeland, P. M., Hayden, D. L., Borba, C. P. C., Louie, P. M., Freudenreich, O., Evins, A. E., Cather, C., & GOFF, D. C. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0905 · Cited by 205 · see citing works
The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146 · see citing works
The impact of clozapine on hospital use: a systematic review and meta-analysis
Land, R., Siskind, D., McArdle, P., Kisely, S., Winckel, K., & Hollingworth, S. A. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12700 · Cited by 141 · see citing works
Self-citationMetformin for clozapine associated obesity: a systematic review and meta-analysis
Siskind, D. J., Leung, J., Russell, A. W., Wysoczanski, D., & Kisely, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156208 · Cited by 122 · see citing works
Self-citationIshøy, P. L., Knop, F. K., Broberg, B. V., Bak, N., Andersen, U. B., Jørgensen, N. R., Holst, J. J., Glenthøj, B. Y., & Ebdrup, B. H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12795 · Cited by 102 · see citing works
Smith, G. C., Vickers, M. H., Cognard, E., & Shepherd, P. R. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.07.011 · Cited by 58 · see citing works
A Classification System to Evaluate Weight Maintainers, Gainers, and Losers
Jeor, S. T. S., Brunner, R. L., Harrington, M. E., Scott, B. J., Daugherty, S. A., Cutter, G., Brownell, K. D., Dyer, A. R., & Foreyt, J. P. (1997) · Journal of the American Dietetic Association · doi:10.1016/s0002-8223(97)00126-0 · Cited by 57 · see citing works
Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49 · see citing works
Self-citationTreatment of clozapine-associated weight gain: a systematic review
Whitney, Z., Procyshyn, R. M., Fredrikson, D. H., & Barr, A. M. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1807-1 · Cited by 42 · see citing works
Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance
Remington, G. J., Teo, C., Wilson, V. S., Chintoh, A. F., Guenette, M. D., Ahsan, Z. A., Giacca, A., & Hahn, M. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0074 · Cited by 28 · see citing works
Mayfield, K., Siskind, D. J., Winckel, K., Hollingworth, S., Kisely, S. R., & Russell, A. W. (2015) · BJPsych Open · doi:10.1192/bjpo.bp.115.001073 · Cited by 12 · see citing works
Self-citationSiskind, D. J. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.116.003103 · Cited by 1 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531 · see citing works
Self-citationAssociation between antipsychotic medication use and diabetes
Holt, R. I. G. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1220-8 · Cited by 162 · see citing works
Siskind, D., Hahn, M., Correll, C. U., Fink‐Jensen, A., Russell, A. W., Bak, N., Broberg, B. V., Larsen, J., Ishøy, P. L., Vilsbøll, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13522 · Cited by 144 · see citing works
Self-citationPsychotropic Drug–Related Weight Gain and Its Treatment
McIntyre, R. S., Kwan, A. T. H., Rosenblat, J. D., Teopiz, K. M., & Mansur, R. B. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230922 · Cited by 119 · see citing works
Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Bhalla, S., Mehan, S., Khan, A., & Rehman, M. U. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104896 · Cited by 108 · see citing works
A Focused Review of the Metabolic Side-Effects of Clozapine
Yuen, J. W. Y., Kim, D. D., Procyshyn, R. M., Panenka, W. J., Honer, W. G., & Barr, A. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.609240 · Cited by 92 · see citing works
Giorgi, R. D., Ghenciulescu, A., Dziwisz, O., Taquet, M., Adler, A., Koychev, I. G., Upthegrove, R., Solmi, M., McCutcheon, R. A., Pillinger, T., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00390-x · Cited by 90 · see citing works
Prasad, F., De, R., Korann, V., Chintoh, A. F., Remington, G., Ebdrup, B. H., Siskind, D., Knop, F. K., Vilsbøll, T., Fink-Jensen, A., et al. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231165169 · Cited by 88 · see citing works
Self-citationWhicher, C. A., Price, H. C., Phiri, P., Rathod, S., Barnard‐Kelly, K., Ngianga, K., Thorne, K., Asher, C., Peveler, R. C., McCarthy, J., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14334 · Cited by 77 · see citing works
Siskind, D. J., Gallagher, E., Winckel, K., Hollingworth, S., Kisely, S. R., Firth, J., Correll, C. U., & Marteene, W. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa191 · Cited by 75 · see citing works
Self-citationCernea, S., Dima, L., Correll, C. U., & Manu, P. (2020) · Drugs · doi:10.1007/s40265-020-01393-x · Cited by 74 · see citing works
Svensson, C. K., Larsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Koyuncu, K., Schjerning, O., Nielsen, J., Ekstrøm, C. T., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12982 · Cited by 66 · see citing works
Siskind, D., Baker, A., Arnautovska, U., Warren, N., Russell, A., DeMonte, V., Halstead, S., Iyer, R., Korman, N., McKeon, G., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00129-4 · Cited by 62 · see citing works
Self-citationStrategies to counter antipsychotic-associated weight gain in patients with schizophrenia
Marteene, W., Winckel, K., Hollingworth, S., Kisely, S. R., Gallagher, E., Hahn, M., Ebdrup, B. H., Firth, J., & Siskind, D. J. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1674809 · Cited by 62 · see citing works
Self-citationAntipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations
Stogios, N., Humber, B. E., Agarwal, S. M., & Hahn, M. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01458-0 · Cited by 60 · see citing works
Vasiliu, O. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12054 · Cited by 60 · see citing works
Rivera, F. B., Lumbang, G. N. O., Gaid, D. R. M., Cruz, L. L. A., Magalong, J. V., Bantayan, N. R. B., Lara-Breitinger, K. M., Gulati, M., & Bakris, G. L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15529 · Cited by 59 · see citing works
The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases
Zhang, L., Zhang, W., & Tian, X. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2021.1924707 · Cited by 54 · see citing works
Bak, M., Campforts, B. C. M., Domen, P. A. E., van Amelsvoort, T., & Drukker, M. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13734 · Cited by 52 · see citing works
Pharmacological interventions for prevention of weight gain in people with schizophrenia
Agarwal, S. M., Stogios, N., Ahsan, Z. A., Lockwood, J., Duncan, M. J., Takeuchi, H., Cohn, T. A., Taylor, V. H., Remington, G. J., Faulkner, G., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013337.pub2 · Cited by 47 · see citing works
Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting
Hu, Y., Zheng, S.-L., Ye, X.-L., Shi, J.-N., Zheng, X.-W., Pan, H.-S., Zhang, Y.-W., Yang, X.-L., & Huang, P. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-200 · Cited by 45 · see citing works
The Management of Obesity in People with Severe Mental Illness: An Unresolved Conundrum
Holt, R. I. G. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000503835 · Cited by 42 · see citing works
Manta, A., Georganta, A., Roumpou, A., Zoumpourlis, V., Spandidos, D. A., Rizos, E. N., & Peppa, Μ. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13479 · Cited by 38 · see citing works
Wang, Y., Wang, D., Cheng, J., Fang, X., Chen, Y., Yu, L., Ren, J., Tian, Y., & Zhang, C. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211035391 · Cited by 36 · see citing works
Ebdrup, B. H., Broberg, B. V., Ishøy, P. L., Bak, N., Andersen, U. B., Jørgensen, N. R., Holst, J. J., Knop, F. K., & Glenthøj, B. Y. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13204 · Cited by 35 · see citing works
GLP‐1 analogs and regional adiposity: A systematic review and meta‐analysis
Akoumianakis, I., Zagaliotis, A., Konstantaraki, M., & Filippatos, T. D. (2023) · Obesity Reviews · doi:10.1111/obr.13574 · Cited by 35 · see citing works
Khaity, A. M., Al-dardery, N. M., Albakri, K. A., Abdelwahab, O. A., Hefnawy, M. T., Yousef, Y. S. A. H., Taha, R. E. W., Swed, S., Hafez, W., Hurlemann, R., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1153648 · Cited by 35 · see citing works
Effect of liraglutide 3.0mg treatment on weight reduction in obese antipsychotic-treated patients
Lee, S. E., Lee, N. Y., Kim, S. H., Kim, K.-A., & Kim, Y. S. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113830 · Cited by 27 · see citing works
Patoulias, D., Michailidis, T., Dimosiari, A., Fragakis, N., Tse, G., & Rizzo, M. (2023) · Biomedicines · doi:10.3390/biomedicines11030669 · Cited by 27 · see citing works
Whicher, C. A., Price, H. C., Phiri, P., Rathod, S., Barnard-Kelly, K. D., Reidy, C., Thorne, K. I., Asher, C. J., Peveler, R., McCarthy, J., et al. (2019) · Trials · doi:10.1186/s13063-019-3689-5 · Cited by 24 · see citing works
GLP-1 receptor agonists and weight loss in schizophrenia – past, present, and future
Trott, M., Arnautovska, U., & Siskind, D. J. (2024) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000952 · Cited by 22 · see citing works
Self-citationBarnard-Kelly, K. D., Whicher, C. A., Price, H. C., Phiri, P., Rathod, S., Asher, C. J., Peveler, R., & Holt, R. I. G. (2022) · BMC Psychiatry · doi:10.1186/s12888-021-03666-5 · Cited by 22 · see citing works
Siskind, D. J., Russell, A. W., Gamble, C., Baker, A., Cosgrove, P., Burton, L., & Kisely, S. R. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.02.015 · Cited by 21 · see citing works
Self-citationSiskind, D. J., Friend, N., Russell, A. W., McGrath, J. J., Lim, C. C. W., Patterson, S., Flaws, D., STEDMAN, T. J., Moudgil, V., Sardinha, S., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-021000 · Cited by 19 · see citing works
Self-citationPatino, L. R., Strawn, J. R., Adler, C. M., Blom, T. J., Welge, J. A., & DelBello, M. P. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.046 · Cited by 18 · see citing works
Lally, J., Loughlin, A. O., Stubbs, B., Guérandel, A., O'Shea, D. B., & Gaughran, F. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1445968 · Cited by 17 · see citing works
Rivera, F. B., Chin, M. N. C., Pine, P. L. S., Ruyeras, M. M. J., Galang, D. J. C., Gandionco, K. M., Morales, B. L. F. D., Climaco, Z. M. V., Bantayan, N. R. B., Magalong, J. V., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2442027 · Cited by 16 · see citing works
Llach, C.-D., Badulescu, S., Tabassum, A., Shah, H., Gill, H., Le, G. H., Vieta, E., McIntyre, R. S., Rosenblat, J. D., & Mansur, R. B. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03261-0 · Cited by 15 · see citing works
Zhuo, C., Xu, Y. J., Wang, H., Zhou, C., Liu, J., Yu, X., Shao, H., Tian, H., Fang, T., Li, Q., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.08.023 · Cited by 15 · see citing works
Semaglutide is effective in type 2 diabetes and obesity with schizophrenia
Noda, K., Kato, T., Nomura, N., Sakai, M., Kubota, S., Hirose, T., Liu, Y., Takahashi, Y., Takao, K., Mizuno, M., et al. (2022) · Diabetology International · doi:10.1007/s13340-022-00590-1 · Cited by 15 · see citing works
Hegde, N. C., Mishra, A., Maiti, R., Mishra, B. R., Mohapatra, D., & Srinivasan, A. (2024) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2024.06.003 · Cited by 14 · see citing works
Lee, K., Akinola, A., & Abraham, S. (2023) · BJPsych Bulletin · doi:10.1192/bjb.2023.29 · Cited by 13 · see citing works
GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
Horská, K., Kučerová, J., & Skrede, S. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.06.005 · Cited by 13 · see citing works
Menon, T., Lee, S. M. L., Gong, X. Y., Wong, S., Le, G. H., Kwan, A. T. H., Teopiz, K. M., Ho, R., Cao, B., Rhee, T. G., et al. (2024) · CNS Spectrums · doi:10.1017/s1092852924000531 · Cited by 12 · see citing works
Analysis of clinical studies on clozapine from 2012-2022
Freibüchler, A., & Seifert, R. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03209-1 · Cited by 11 · see citing works
Jia, I.-I.-T. T., Bloomfield, G. C., Chen, M. Y., Cunningham, M. H., Azagury, D. E., Alimi, Y., & Prindeze, N. J. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-12086-5 · Cited by 10 · see citing works
GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis
Alves, K. M., da Silva, M. T., Kramer, C. K., & Viana, L. V. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf150 · Cited by 9 · see citing works
Siskind, D. J., Baker, A., Russell, A. W., Warren, N., Robinson, G., Parker, S., Medland, S. E., Kisely, S. R., Hager, T., & Arnautovska, U. (2023) · BJPsych Open · doi:10.1192/bjo.2023.532 · Cited by 9 · see citing works
Self-citationNguyen, A., Smith, E., Hashemy, H., Agarwal, S. M., Hahn, M., Paterson, A. D., & Dash, S. (2024) · Clinical Obesity · doi:10.1111/cob.12676 · Cited by 9 · see citing works
Psychische und neurokognitive Erkrankungen und Diabetes mellitus (Update 2023)
Abrahamian, H., Kautzky‐Willer, A., Rießland-Seifert, A., Lebherz-Eichinger, D., Fasching, P., Ebenbichler, C. F., Kautzky, A., & Toplak, H. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02117-9 · Cited by 8 · see citing works
GLP-1 agonists for metabolic disorders in schizophrenia
Kouidrat, Y., & Amad, A. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.09.019 · Cited by 8 · see citing works
Schizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 8 · see citing works
Miedlich, S. U., & Lamberti, J. S. (2025) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15301 · Cited by 7 · see citing works
Seiter, H. T., Fellendorf, F. T., Popkova, D., & Reininghaus, E. Z. (2025) · International Journal of Bipolar Disorders · doi:10.1186/s40345-025-00397-4 · Cited by 7 · see citing works
Exercise ameliorates skeletal muscle insulin resistance by modulating GRK4-mediated D1R expression
Tao, Y., Luo, W., Chen, Y., Chen, C., Chen, S., Li, X., Chen, K., & Zeng, C. (2023) · Clinical Science · doi:10.1042/cs20230664 · Cited by 7 · see citing works
Namara, K. M., Alzubaidi, H., Murray, M., Samorinha, C., Dunbar, J., Versace, V. L., & Castle, D. J. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51701 · Cited by 7 · see citing works
Antipsychotic‐induced weight gain: Is the weight over? New guidelines needed
de Boer, N., & Cahn, W. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13485 · Cited by 6 · see citing works
Bing-guo, X., Hui, W., Wang, S., & Lijuan, D. (2021) · Journal of Acupuncture and Tuina Science · doi:10.1007/s11726-021-1235-y · Cited by 5 · see citing works
Grywińska, W. B., & Głowacka, A. (2023) · Postępy Psychiatrii i Neurologii · doi:10.5114/ppn.2023.132493 · Cited by 5 · see citing works
Goetz-Kundera, Z., Przekopińska, B., Walichniewicz, P., Niewada, M., & Lew‐Starowicz, M. (2025) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2025.152632 · Cited by 4 · see citing works
Wang, X., Lew, W. Y., Yang, Y., Zhang, N., Bu, J., Li, Z., Fitzpatrick, M., Bonnitcha, P., SULLIVAN, D. R., Zhang, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18101549 · Cited by 4 · see citing works
Srisurapanont, M., Suttajit, S., Likhitsathian, S., Suradom, C., & Maneeton, B. (2026) · The International Journal of Psychiatry in Medicine · doi:10.1177/00912174261422822 · Cited by 4 · see citing works
Diagnosis and management of hyperglycaemia in patients treated with antipsychotic drugs
Kosmalski, M., Różycka-Kosmalska, M., Basiak, M., Okopień, B., & Pietras, T. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0071 · Cited by 4 · see citing works
De, R., Prasad, F., Stogios, N., Burin, L. M., Ebdrup, B. H., Knop, F. K., Hahn, M., & Agarwal, S. M. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2254698 · Cited by 4 · see citing works
Varshney, K., Panda, S., Fernando, D. M. H., Sava, S. T., & Khan, T. (2025) · Obesities · doi:10.3390/obesities5040072 · Cited by 3 · see citing works
Drugs and chemical substances inducing diabetes - review of the literature
Oleksa, P., Żuraw, D., Jasiński, K., Sobczyk, M., Porzak, M., Sodolska, A., & Haczkur-Pawłowska, K. (2024) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.183 · Cited by 3 · see citing works
Uhrenholt, N. G., Ganeshalingam, A. A., Arnfred, S., Gæde, P., Pedersen, A. K., Larsen, P. V., Frystyk, J., & Bilenberg, N. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.02.009 · Cited by 2 · see citing works
Lee, S., Kim, M., Trott, M., Siskind, D. J., & Kim, J. H. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261456190 · Cited by 2 · see citing works
Self-citationMedikamente zur Behandlung von Essstörungen und Adipositas
Himmerich, H., & Benkert, O. (2016) · Springer eBooks · doi:10.1007/978-3-662-50333-1_9 · Cited by 2 · see citing works
De, R., Amin Alfatwa, Y., Kanagasundaram, P., Saragosa, J. E., Chan, J., Remington, G., Retnakaran, R., Sanches, M., Sockalingam, S., Agarwal, S. M., et al. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf236 · Cited by 1 · see citing works
“18 , 22 – 26 Among this GLP-1RA drug class, semaglutide has emerged as the next-generation, weekly subcutaneous medication, with evidence of good tolerability and superior efficacy when compared to first generation GLP-1RAs.”
Siskind, D. J., Bull, C. F., Suetani, S., Warren, N., Suraev, A. S., McGregor, I. S., Kisely, S. R., Monte, V. E. D., Trott, M., Shine, M., et al. (2024) · BJPsych Open · doi:10.1192/bjo.2024.748 · Cited by 1 · see citing works
Self-citationGreat Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital
Shannon, K. C., & Shyh, G. I. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241294122 · Cited by 1 · see citing works
Person Centered Approach and Challenges in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_7 · Cited by 1 · see citing works
Wong, S.-Y., Chan, S., Mo, Y.-M. F., Tsoh, J., Wong, W.-H. O., Yu, T.-M., Chan, S.-M. S., & Lai, H.-M. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbag050 · Cited by 1 · see citing works
Lappin, J., Bolton, P., Smith, G., Chua, X., Grattan, S., Samaras, K., Day, R., Popovic, G. C., O׳Donnell, M., Buten, S., et al. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.06.021 · Cited by 1 · see citing works
Seijas‐Amigo, J., Salgado‐Barreira, Á., Eiras, S., Arias-Rivas, S., Rodríguez-Carnero, G., Rodríguez‐Mañero, M., & González‐Juanatey, J. R. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag101 · Cited by 1 · see citing works
Sobral, M. V. S., Menechini, R. B., da Silva, J. B. C., de Vasconcelos, A. V., Graciolli, L. H. M. D. S. G., Maciel, R. C., Monteiro, A., Amador, W. F. O., & Acuia, T. A. D. S. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.06.025 · Cited by 1 · see citing works
Zheng, Y., Meyerowitz‐Katz, G., Bramwell, S., Jayaballa, R., Assur, Y., Vasani, D., Ganapathy, R., MABERLY, G. F., & Brakoulias, V. (2022) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001590 · Cited by 1 · see citing works
Metabolische unerwünschte Arzneimittelwirkungen von Psychopharmaka
Gahr, M. (2024) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2405-5087 · Cited by 1 · see citing works
Medikamente zur Behandlung von Essstörungen und Adipositas
Himmerich, H., & Benkert, O. (2020) · Springer eBooks · doi:10.1007/978-3-662-61753-3_9 · Cited by 1 · see citing works
Medikamente zur Behandlung von Essstörungen und Adipositas
Himmerich, H., & Benkert, O. (2023) · Springer eBooks · doi:10.1007/978-3-662-67685-1_9 · Cited by 1 · see citing works
Costa-Dookhan, K. A. (2020) · TSpace (University of Toronto)
Siddiqi, N., Stadler, M., & Holt, R. I. G. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch65
Case 8: From prodrome to psychosis: early-onset schizophrenia
Strawn, J. R., & Stahl, S. M. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009049719.009
Metabolische unerwünschte Arzneimittelwirkungen von Psychopharmaka
Gahr, M. (2025) · Diabetes aktuell · doi:10.1055/a-2539-1129
Can we run away from the metabolic side effects of antipsychotics?
Akcan, M., & Wright, D. C. (2025) · Translational Exercise Biomedicine · doi:10.1515/teb-2025-0016
Meftah, A., Yoade, B., Cowart, C., Choi, A., Popoola, O., Afe, O., Efremoff, S., Ezema, C., Johnson, B. O., Lawrence, J., et al. (2026) · Cureus · doi:10.7759/cureus.109089
Psychische und neurokognitive Erkrankungen und Diabetes mellitus (Update 2026)
Abrahamian, H., Kautzky‐Willer, A., Rießland-Seifert, A., Kautzky, A., Brix, J. M., Harb, B. M., Beer, D., Lebherz-Eichinger, D., Fasching, P., & Toplak, H. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02654-z
GLP-1 receptor agonists for the management of obesity in individuals treated with antipsychotics
Patoulias, D., Teperikidis, E., Mourtzos, M.-A., Koufakis, T., & Karakasis, P. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106977
Medikamente zur Behandlung von Essstörungen und Adipositas
Himmerich, H. (2026) · Springer eBooks · doi:10.1007/978-3-662-72452-1_9
Abbas, N., Memon, A. A., Zulfiqar, R., Noon, A. Z., Shah, S. M. A., Panhwar, K., Sadia, Z., Khan, M. S., Akbar, M. B., Iftikhar, S., et al. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002234
Kaczynski, M., Zureikat, R. M., Kaczynski, M. R., Sitarz, R., & Karakuła‐Juchnowicz, H. (2026) · Biomedicines · doi:10.3390/biomedicines14091957
Moubarak, E. S., Elgendy, M. S., Elkoumi, O., Ibrahim, A. A., Manasrah, A., Ahmad, J., Hassan, M. A., Rageh, E. M., Mohamed, A. A., Elzahaby, A., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261478625
Energetic dysregulations in psychotic disorders: Targets for new therapeutics
Anderson, J., Sonntag, K., Le, T. D. V., Shannon, K., Wang, C., Du, F., Chen, X., McPhie, D. L., Öngür, D., Cohen, B. M., et al. (2026) · FEBS Journal · doi:10.1111/febs.70719
Cotrik, E. M., & da Silva, A. G. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.10.012
Fagiolini, A. M., & Cuomo, A. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.10.039
Zhou, L., Zhang, Y., Shen, C., & Wu, F. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04206-4
Gędek, A., Modrzejewski, S., Polański, K., Waśniewska, L., Molero, P., Wichniak, A., Dominiak, M., & McIntyre, R. S. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.113886
- Authors
- Siskind, D. J., Russell, A. W., Gamble, C., Winckel, K., Mayfield, K., Hollingworth, S., Hickman, I., Siskind, V., & Kisely, S.
- Affiliations
- The University of Queensland (AU)
- Queensland Centre for Mental Health Research (AU)
- Logan Hospital (AU)
- School of Pharmacy University of Queensland Brisbane Australia
- Princess Alexandra Hospital (AU)
- Queensland University of Technology (AU)
- Corresponding author
- Siskind, Dan J
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-12-19
- Volume
- 20
- Issue
- 4
- Pages
- 1050-1055
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2772389138
- Cited by
- 98
- References
- 16
- Citations by year
- 2026: 19 · 2025: 16 · 2024: 14 · 2023: 14 · 2022: 10 · 2021: 8 · 2020: 5 · 2019: 5 · 2018: 6 · 2016: 1
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Griffith Research Online (submittedVersion)
- Funders
- Rebecca L. Cooper Medical Research Foundation
- National Health and Medical Research Council (ECF APP1111136)
- PA Research Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- clozapine, exenatide, schizophrenia, obesity, type 2 diabetes, GLP-1 receptor agonists, weight loss, HbA1c, fasting blood glucose, metabolic syndrome
- MeSH terms
- Exenatide, Adolescent, Adult, Blood Glucose, Clozapine, Diabetes Mellitus, Type 2, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Obesity, Pilot Projects, Schizophrenia, Weight Loss, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
